Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKEX7O)

• Drug Name: Plecanatide Drug Info
• Synonyms: Trulance

Indication

Disease Entry	ICD 11	Status	REF
Chronic idiopathic constipation	DC32	Approved	[1]
Irritable bowel syndrome	DD91.0	Approved	[2]
Crohn disease	DD70	Phase 3	[3]

• Cross-matching ID:
  PubChem CID: 70693500
  CAS Number: CAS 467426-54-6
  TTD Drug ID: DMKEX7O
  ACDINA Drug ID: D00539

Molecule-Related Drug Atlas

Drug(s) Targeting Guanylyl cyclase C (GUCY2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Linaclotide	DM4EGV0	Irritable bowel syndrome	DD91.0	Approved	[5]
MD-1100	DM4IAKR	Constipation	DD91.1	Approved	[6]
SP-333	DM2UKJV	Ulcerative colitis	DD71	Phase 2	[7]
MLN0264	DMI4E9K	Gastrointestinal cancer	2C11	Phase 2	[8]
PF-07062119	DME3BJL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Guanylyl cyclase C (GUCY2C)	TTLDPRG	GUC2C_HUMAN	Modulator	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9-26.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
• [6] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] J Clin Oncol 31, 2013 (suppl; abstr TPS3646).
• [9] Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.